A PHASE 2, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF 6 OR 8 WEEKS OF TREATMENT WITH SIMEPREVIR, DACLATASVIR AND SOFOSBUVIR IN TREATMENT-NAÏVE SUBJECTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION.

Registry ID

TMC435HPC2013

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

JANSSEN R&D IRELAND

Start date

2015-08-17

Completion date

2016-06-30

Last update

2015-02-04

Conditions

• HEPATITIS C VIRUS GENOTYPE 1

Related clinical trials

• AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE LONG-TERM OUTCOMES WITH ABT-450/RITONAVIR/ABT-267 (ABT-450/R/ABT-267) AND ABT-333 WITH OR WITHOUT RIBAVIRIN (RBV) IN ADULTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (TOPAZ-I).
• A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12- OR 8-WEEK TREATMENT REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NAÏVE AND -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS
• A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A 12-WEEK REGIMEN OF SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR IN TREATMENT-NAÏVE OR -EXPERIENCED SUBJECTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS INFECTION AND CIRRHOSIS
• A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C AND ADVANCED FIBROSIS OR COMPENSATED CIRRHOSIS
• A PHASE 3 EVALUATION OF A DACLATASVIR/ASUNAPREVIR/BMS-791325 FIXED DOSE COMBINATION (FDC) IN NON-CIRRHOTIC SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C
• "A PHASE 3 BLINDED RANDOMIZED STUDY OF PEGINTERFERON LAMBDA-1A AND RIBAVIRIN COMPARED TO PEGINTERFERON ALFA-2A AND RIBAVIRIN, EACH ADMINISTERED WITH TELAPREVIR IN SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C WHO ARE TREATMENT-NAIVE OR RELAPSED ON TREATMENT WITH PEGINTERFERON ALFA AND RIBAVIRIN."

View on source registry